This is the first in a series of OHE Insights on the history, implications and possible impact of President Trump’s Executive Order on a “Most Favoured Nation” (MFN) pricing model for pharmaceuticals.

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...